Clinical Report: A Case Report on Severe 3M Syndrome Induced by Immune Checkpoint Inhibitors
Overview
This report details a case of severe 3M syndrome induced by immune checkpoint inhibitors in a patient with cervical cancer. The syndrome, characterized by the combination of myocarditis, myositis, and myasthenia gravis, led to rapid clinical deterioration and ultimately resulted in the patient's death despite aggressive treatment.
Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, particularly in advanced cervical cancer, but they can cause serious immune-related adverse events (irAEs). Among these, the overlap of myocarditis, myositis, and myasthenia gravis, known as 3M syndrome, poses significant risks, including high mortality rates. Early recognition and intervention are critical to improving outcomes for patients experiencing these toxicities.
Data Highlights
No numerical data available in the article.
Key Findings
A 65-year-old female developed 3M syndrome after receiving anti-PD-1 therapy for cervical cancer.
Initial symptoms included subtle neuromuscular signs such as ptosis and facial weakness.
Acute heart failure and atrial fibrillation occurred shortly after the onset of neuromuscular symptoms.
Despite treatment with high-dose steroids and IVIG, the patient succumbed to respiratory failure.
3M syndrome can present insidiously, complicating timely diagnosis and management.
Clinical Implications
Clinicians should maintain a high index of suspicion for 3M syndrome in patients receiving ICIs, especially when neuromuscular symptoms arise. Proactive monitoring and immediate immunosuppressive treatment are essential to mitigate the risks associated with this potentially fatal syndrome.
Conclusion
This case underscores the need for heightened awareness and systematic approaches to monitor and manage irAEs like 3M syndrome in patients undergoing immunotherapy for cancer.
